

Mar 6, 2025

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

This is to inform that AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 for Sodium Zirconium Cyclosilicate powder for oral suspension 5 g and 10 g (Lokelma).

Through this approval, Sodium Zirconium Cyclosilicate is indicated for the treatment of hyperkalaemia in adult patients.

The receipt of this permission paves way for the launch of Sodium Zirconium Cyclosilicate powder for oral suspension 5 g and 10 g (Lokelma) in India for the above specified indications, subject to the receipt of related statutory approvals, if any.

We request you to take the above intimation on record.

Thanking you

Yours faithfully

For AstraZeneca Pharma India Limited

Manasa. R

Company Secretary